Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus

Clinical and Experimental Rheumatology

Volumn 26, Issue 5 SUPPL. 51, 2008, Pages

  Avalos, Ingrid ^a   Rho, Young Hee ^b   Chung, Cecilia P ^c   Stein, C Michael ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; Inflammation; Rheumatoid arthritis; Systemic lupus erythematosus

Indexed keywords

ASPARTATE AMINOTRANSFERASE; ATLIZUMAB; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD40 LIGAND; CHOLESTEROL; CORTICOSTEROID; GLUCOCORTICOID; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOPROTEGRIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PREDNISOLONE; PREDNISONE; PROTEGRIN; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

ARTERIAL WALL THICKNESS; ARTERY CALCIFICATION; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY; DISEASE ACTIVITY; EARLY DIAGNOSIS; ERYTHROCYTE SEDIMENTATION RATE; FRAMINGHAM RISK SCORE; HEART INFARCTION; HUMAN; INFLAMMATION; INSULIN RESISTANCE; KIDNEY DYSFUNCTION; METABOLIC SYNDROME X; MORTALITY; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SCORING SYSTEM; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; TRIACYLGLYCEROL BLOOD LEVEL;

ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PREVALENCE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 55349120124     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (113)

1. PINCUS T, CALLAHAN LF: Taking mortality in rheumatoid arthritis seriously-predictive markers, socioeconomic status and comorbidity. J Rheumatol 1986; 13: 841-5.
2. NAZ SM, SYMMONS DP: Mortality in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007; 21: 871-83.
3. SOLOMON DH, KARLSON EW, RIMM EB et al.: Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107: 1303-7.
4. BANERJEE S, COMPTON AP, HOOKER RS et al.: Cardiovascular outcomes in male veterans with rheumatoid arthritis. Am J Cardiol 2008; 101: 1201-5.
5. HAN C, ROBINSON DW JR, HACKETT MV, PARAMORE LC, FRAEMAN KH, BALA MV: Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006; 33: 2167-72.
6. WOLFE F, FREUNDLICH B, STRAUS WL: Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 2003; 30: 36-40.
7. TURESSON C, JARENROS A, JACOBSSON L: Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study. Ann Rheum Dis 2004; 63: 952-5.
8. CHUNG CP, OESER A, AVALOS I et al.: Utility of the Framingham risk score to predict the presence of coronary atherosclerosis in patients with rheumatoid arthritis. Arthritis Res Ther 2006; 8: R186.
9. DEL RINCON I, WILLIAMS K, STERN MP, FREEMAN GL, ESCALANTE A: High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44: 2737-45.
10. SOLOMON DH, CURHAN GC, RIMM EB, CANNUSCIO CC, KARLSON EW: Cardiovascular risk factors in women with and without rheumatoid arthritis. Arthritis Rheum 2004; 50: 3444-9.
11. GONZALEZ A, MARADIT KH, CROWSON CS et al.: Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Ann Rheum Dis 2008; 67: 64-9.
12. FORD ES, GILES WH, MOKDAD AH: The distribution of 10-Year risk for coronary heart disease among US adults: findings from the National Health and Nutrition Examination Survey III. J Am Coll Cardiol 2004; 43: 1791-6.
13. KIP KE, MARROQUIN OC, KELLEY DE et al.: Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study. Circulation 2004; 109: 706-13.
14. LAAKSONEN DE, LAKKA HM, NISKANEN LK, KAPLAN GA, SALONEN JT, LAKKA TA: Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 2002; 156: 1070-7.
15. LAKKA HM, LAAKSONEN DE, LAKKA TA et al.: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-16.
16. REILLY MP, WOLFE ML, RHODES T, GIRMAN C, MEHTA N, RADER DJ: Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis. Circulation 2004; 110: 803-9.
17. CHUNG CP, OESER A, SOLUS JF et al.: Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis 2008; 196: 756-63.
18. HALL FC, DALBETH N: Disease modification and cardiovascular risk reduction: two sides of the same coin? Rheamatology (Oxford) 2005; 44: 1473-82.
19. RIDKER PM, CUSHMAN M, STAMPFER MJ, TRACY RP, HENNEKENS CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9.
20. RIDKER PM, HENNEKENS CH, BURING JE, RIFAI N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-43.
21. LINDSAY AC, CHOUDHURY RP: Form to function: current and future roles for atherosclerosis imaging in drug development. Nat Rev Drug Discov 2008; 7: 517-29.
22. AGATSTON AS, JANOWITZ WR, HILDNER FJ, ZUSMER NR, VIAMONTE M JR, DETRANO R: Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990; 15: 827-32.
23. KUMEDA Y, INABA M, GOTO H et al.: Increased thickness of the arterial intimamedia detected by ultrasonography in patients with rheumatoid arthritis. Arthritis Rheum 2002; 46: 1489-97.
24. PARK YB, AHN CW, CHOI HK et al.: Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. Arthritis Rheum 2002; 46: 1714-9.
25. ROMAN MJ, MOELLER E, DAVIS A et al.: Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med 2006; 144: 249-56.
26. CHUNG CP, OESER A, RAGGI P et al.: Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum 2005; 52: 3045-53.
27. WU JT, WU LL: Association of soluble markers with various stages and major events of atherosclerosis. Ann Clin Lab Sci 2005; 35: 240-50.
28. KOENIG W, KHUSEYINOVA N: Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol 2007; 27: 15-26.
29. PASCERI V, YEH ET: A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation 1999; 100: 2124-6.
30. MARADIT-KREMERS H, NICOLA PJ, CROWSON CS, BALLMAN KV, GABRIEL SE: Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005; 52: 722-32.
31. PINCUS T: Long-term outcomes in rheumatoid arthritis. Br J Rheumatol 1995; 34 (Suppl. 2): 59-73.
32. NAVARRO-CANO G, DEL R, I, POGOSIAN S, ROLDAN JF, ESCALANTE A: Association of mortality with disease severity in rheumatoid arthritis, independent of comorbidity. Arthritis Rheum 2003; 48: 2425-33.
33. KRAUSE D, SCHLEUSSER B, HERBORN G, RAU R: Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 2000; 43: 14-21.
34. CHOI HK, HERNAN MA, SEEGER JD, ROBINS JM, WOLFE F: Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359: 1173-7.
35. JONSSON SW, BACKMAN C, JOHNSON O et al.: Increased prevalence of atherosclerosis in patients with medium term rheumatoid arthritis. J Rheumatol 2001; 28: 2597-602.
36. WÅLLBERG-JONSSON S, OHMAN M, RÄNTAPÄÄ-DAHLQVIST S: Which factors are related to the presence of atherosclerosis in rheumatoid arthritis? Scand J Rheumatol 2004; 33: 373-9.
37. DESSEIN PH, JOFFE BI, SINGH S: Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther 2005; 7: R634-R643.
38. DAZA L, AGUIRRE M, JIMENEZ M, HERRERA R, BOLLAIN JJ: Common carotid intimamedia thickness and von Willebrand factor serum levels in rheumatoid arthritis female patients without cardiovascular risk factors. Clin Rheumatol 2007; 26: 533-7.
39. DESSEIN PH, TOBIAS M, VELLER MG: Metabolic syndrome and subclinical atherosclerosis in rheumatoid arthritis. J Rheumatol 2006; 33: 2425-32.
40. SURDACKI A, MARTENS-LOBENHOFFER J, WLOCH A et al.: Elevated plasma asymmetric dimethyl-L-arginine levels are linked to endothelial progenitor cell depletion and carotid atherosclerosis in rheumatoid arthritis. Arthritis Rheum 2007; 56: 809-19.
41. DESSEIN PH, NORTON GR, WOODIWISS AJ, JOFFE BI, WOLFE F: Influence of nonclassical cardiovascular risk factors on the accuracy of predicting subclinical atherosclerosis in rheumatoid arthritis. J Rheumatol 2007; 34: 943-51.
42. ASANUMA Y, CHUNG CP, OESER A et al.: Serum osteoprotegerin is increased and independently associated with coronary-artery atherosclerosis in patients with rheumatoid arthritis. Atherosclerosis 2007; 195: e135-e141.
43. CHAIT A, HAN CY, ORAM JF, HEINECKE JW: Thematic review series: The immune system and atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? J Lipid Res 2005; 46: 389-403.
44. PACKARD RR, LIBBY P: Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 2008; 54: 24-38.
45. NARANJO A, SOKKA T, DESCALZO MA et al.: Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 2008; 10: R30.
46. SHOLTER DE, ARMSTRONG PW: Adverse effects of corticosteroids on the cardiovascular system. Can J Cardiol 2000; 16: 505-11.
47. DEL RINCON I, O'LEARY DH, HAAS RW, ESCALANTE A: Effect of glucocorticoids on the arteries in rheumatoid arthritis. Arthritis Rheum 2004; 50: 3813-22.
48. SKOOG T, DICHTL W, BOQUIST S et al.: Plasma tumour necrosis factor-alpha and early carotid atherosclerosis in healthy middle-aged men. Eur Heart J 2002; 23: 376-83.
49. CESAR]I M, PENNINX BW, NEWMAN AB et al.: Inflammatory markers and cardiovascular disease (The Health, Aging and Body Composition [Health ABC] Study). Am J Cardiol 2003; 92: 522-8.
50. HURLIMANN D, FORSTER A, NOLL G et al.: Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002; 106: 2184-7.
51. KOMAI N, MORITA Y, SAKUTA T, KUWABARA A, KASHIHARA N: Anti-tumor necrosis factor therapy increases serum adiponectin levels with the improvement of endothelial dysfunction in patients with rheumatoid arthritis. Mod Rheumatol 2007; 17: 385-90.
52. DEL PORTO F, LAGANA B, LAI S et al.: Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. Rheumatology (Oxford) 2007; 46: 1111-5.
53. NISHIMOTO N, YOSHIZAKI K, MIYASAKA N et al.: Treatment of rheumatoid arthritis with humanized anti-interieukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004; 50: 1761-9.
54. MAINI RN, TAYLOR PC, SZECHINSKI J et al.: Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006; 54: 2817-29.
55. BULKLEY BH, ROBERTS WC: The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. A study of 36 necropsy patients. Am J Med 1975; 58: 243-64.
56. UROWITZ MB, BOOKMAN AA, KOEHLER BE, GORDON DA, SMYTHE HA, OGRYZLO MA: The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976; 60: 221-5.
57. Z MB, GLADMAN DD: Mortality in systemic lupus erythematosus: the bimodal pattern revisited. Q J Med 1985; 55: 87-98.
58. MANZI S, MEILAHN EN, RAIRIE JE et al.: Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus crythematosus: comparison with the Framingham Study. Am J Epidemiol 1997; 145: 408-15.
59. WARD MM: Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 1999; 42: 338-46.
60. PETRI M, SPENCE D, BONE LR, HOCHBERG MC: Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. Medicine (Baltimore) 1992; 71: 291-302.
61. BORBA EF, BONFA E: Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 1997; 6: 533-9.
62. BRUCE IN, UROWITZ MB, GLADMAN DD, IBANEZ D, STEINER G: Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum 2003; 48: 3159-67.
63. OESER A, CHUNG CP, ASANUMA Y, AVALOS I, STEIN CM: Obesity is an independent contributor to functional capacity and inflammation in systemic lupus erythematosus. Arthritis Rheum 2005; 52: 3651-9.
64. GLADMAN DD, UROWITZ MB: Morbidity in systemic lupus erythematosus. J Rheumatol Suppl 1987; 14 (Suppl. 13): 223-6.
65. DORIA A, SHOENFELD Y, WU R et al.: Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2003; 62: 1071-7.
66. BRUCE IN, UROWITZ MB, GLADMAN DD, HALLETT DC: Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol 1999; 26: 2137-43.
67. CHUNG CP, OESER A, RAGGI P et al.: Lipoprotein subclasses and particle size determined by nuclear magnetic resonance spectroscopy in systemic lupus erythematosus. Clin Rheumatol 2008 April 18.
68. CHUNG CP, OESER A, AVALOS I, RAGGI P, STEIN CM: Cardiovascular risk scores and the presence of subclinical coronary artery atherosclerosis in women with systemic lupus erythematosus. Lupus 2006; 15: 562-9.
69. CHUNG CP, AVALOS I, OESER A et al.: High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis 2007; 66: 208-14.
70. CHUNG CP, OESER A, SOLUS JF et al.: Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum 2008; 58: 2105-12.
71. ASANUMA Y, OESER A, SHINTANI AK et al.: Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2407-15.
72. MANGER K, KUSUS M, FORSTER C et al.: Factors associated with coronary artery calcification in young female patients with SLE. Ann Rheum Dis 2003; 62: 846-50.
73. KIANI AN, MAGDER L, PETRI M: Coronary calcium in systemic lupus erythematosus is associated with traditional cardiovascular risk factors, but not with disease activity. J Rheumatol 2008; 35: 1300-6.
74. ROMAN MJ, SHANKER BA, DAVIS A et al.: Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399-406.
75. SATO H, MIIDA T, WADA Y et al.: Atherosclerosis is accelerated in patients with long-term well-controlled systemic lupus erythematosus (SLE). Clin Chim Acta 2007; 385: 35-42.
76. SOUZA AW, HATTA FS, MIRANDA F JR, SATO EI: Atherosclerotic plaque in carotid arteries in systemic lupus erythematosus: frequency and associated risk factors. Sao Paulo Med J 2005; 123: 137-42.
77. ROMAN MJ, CROW MK, LOCKSHIN MD et al.: Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2007; 56: 3412-9.
78. THOMPSON T, SUTTON-TYRRELL K, WILDMAN RP et al.: Progression of carotid intima-media thickness and plaque in women with systemic lupus erythemarosus. Arthritis Rheum 2008; 58: 835-42.
79. CELERMAJER DS, SORENSEN KE, BULL C, ROBINSON J, DEANFIELD JE: Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol 1994; 24: 1468-74.
80. EL-MAGADMI M, BODILL H, AHMAD Y et al.: Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation 2004; 110: 399-404.
81. LIMA DS, SATO EI, LIMA VC, MIRANDA F JR, HATTA FH: Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J Rheumatol 2002; 29: 292-7.
82. ASANUMA Y, CHUNG CP, OESER A et al.: Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J Rheumatol 2006; 33: 539-45.
83. BOMBARDIER C, GLADMAN DD, UROWITZ MB, CARON D, CHANG CH: Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630-40.
84. RHO YH, CHUNG CP, OESER A et al.: Novel cardiovascular risk factors in premature coronary atherosclerosis associated with systemic lupus erythematosus. J Rheumatol 2008 July 15.
85. SVENUNGSSON E, FEI GZ, JENSEN-URSTAD K, DE FU, HAMSTEN A, FROSTEGARD J: TNF-alpha: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease. Lupus 2003; 12:454-61.
86. SAELAND S, DUVERT V, MOREAU I, BANCHEREAU J: Human B cell precursors proliferate and express CD23 after CD40 ligation. J Exp Med 1993; 178: 113-20.
87. LEDERMAN S, YELLIN MJ, CLEARY AM et al.: T-BAM/CD40-L on helper T lymphocytes augments lymphokine-induced B cell Ig isotype switch recombination and rescues B cells from programmed cell death. J Immunol 1994; 152:2163-71.
88. MACH F, SCHONBECK U, LIBBY P: CD40 signaling in vascular cells: a key role in atherosclerosis? Atherosclerosis 1998; 137 (Suppl.): S89-S95.
89. MACH F, SCHONBECK U, SUKHOVA GK et al.: Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA 1997; 94: 1931-6.
90. SCHONBECK U, MACH F, SUKHOVA GK et al.: CD40 ligation induces tissue factor expression in human vascular smooth muscle cells. Am J Pathol 2000; 156: 7-14.
91. YAZDANY J, DAVIS J: The role of CD40 ligand in systemic lupus erythematosus. Lupus 2004; 13: 377-80.
92. LEE AB, GODFREY T, ROWLEY KG et al.: Traditional risk factor assessment does not capture the extent of cardiovascular risk in systemic lupus erythematosus. Intern Med J 2006; 36: 237-43.
93. VAKKALANKA RK, WOO C, KIROU KA, KOSHY M, BERGER D, CROW MK: Elevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera. Arthritis Rheum 1999; 42: 871-81.
94. KIANI A, MAHONEY JA, PETRI M: Soluble CD154 is not associated with atherosclerosis in systemic lupus erythematosus. J Rheumatol 2007; 34: 969-72.
95. McMAHON M, HAHN BH: Atherosclerosis and systemic lupus erythematosus: mechanistic basis of the association. Curr Opin Immunol 2007; 19: 633-9.
96. AVALOS I, CHUNG CP, OESER A et al.: Oxidative Stress in Systemic Lupus Erythematosus: Relationship to Disease Activity and Symptoms. Lupus 2007; 16: 195-200.
97. NAVAB M, HAMA SY, REDDY ST et al.: Oxidized lipids as mediators of coronary heart disease. Curr Opin Lipidol 2002; 13: 363-72.
98. ANSELL BJ, NAVAB M, HAMA S et al.: Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003; 108: 2751-6.
99. MCMAHON M, GROSSMAN J, FITZGERALD J et al.: Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006; 54: 2541-9.
100. WALD DS, LAW M, MORRIS JK: Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002; 325: 1202.
101. PETRI M, ROUBENOFF R, DALLAL GE, NADEAU MR, SELHUB J, ROSENBERG IH: Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996; 348: 1120-4.
102. VON FELDT JM, SCALZI LV, CUCCHIARA AJ et al.: Homocysteine levels and disease duration independently correlate with coronary artery calcification in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2220-7.
103. LONN E, YUSUF S, ARNOLD MJ et al.: Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354: 1567-77.
104. SARNAK MJ, LEVEY AS, SCHOOLWERTH AC et al.: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003; 42: 1050-65.
105. FALASCHI F, RAVELLI A, MARTIGNONI A et al.: Nephrotic-range proteinuria, the major risk factor for early atherosclerosis in juvenile-onset systemic lupus erythematosus. Arthritis Rheum 2000; 43: 1405-9.
106. BRUCE IN: 'Not only... but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford) 2005; 44: 1492-502.
107. MANZI S, SELZER F, SUTTON-TYRRELL K et al.: Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999; 42: 51-60.
108. MACGREGOR AJ, DHILLON VB, BINDER A et al.: Fasting lipids and anticardiolipin anti-bodies as risk factors for vascular disease in systemic lupus erythematosus. Ann Rheum Dis 1992; 51: 152-5.
109. DEL RINCON I, WILLIAMS K, STERN MP, FREEMAN GL, O'LEARY DH, ESCALANTE A. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 2003; 48: 1833-40.
110. GONZALEZ-GAY MA, GONZALEZ-JUANATEY C, PINEIRO A, GARCIA-PORRUA C, TESTA A, LLORCA J: High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 1219-23.
111. DEL RINCON I, FREEMAN GL, HAAS RW, O'LEARY DH, ESCALANTE A: Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. Arthritis Rheum 2005; 52: 3413-23.
112. PAHOR A, HOJS R, GORENJAK M, ROZMAN B: Accelerated atherosclerosis in pre-menopausal female patients with rheumatoid arthritis. Rheumatol Int 2006 27: 119-23.
113. HANNAWI S, HALUSKA B, MARWICK TH, THOMAS R: Atherosclerotic disease is increased in recent-onset rheumatoid arthritis: a critical role for inflammation. Arthritis Res Ther 2007; 9: R116.